Results for this period
Interim period (second quarter)1 January 2026–30 June 2026ConsolidatedIFRSThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ thousand).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Research and development expenses increased by ¥170 million due to higher development costs for emixustat hydrochloride. Selling, general and administrative expenses increased by ¥28 million due mainly to higher share-based compensation expenses and patent-related expenses. The ramp-up in overseas sales of the myopia progression care device has been delayed, and the operating loss and negative operating cash flow continue.
A description of material events and other matters is included. Although the company recognizes that circumstances exist that raise substantial doubt about the going concern assumption, it has secured the funds necessary for its business activities for the foreseeable future and has determined that no material uncertainty exists. There are no matters to be disclosed in the notes on the going concern assumption.
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | IFRS |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 January 2026–30 June 2026 |
| Net Sales | ¥8 million (YoY -39.8%) |
| Operating profit | ¥-650 million |
| Ordinary income | ¥-649 million |
| Profit attributable to owners of the parent | ¥-649 million |
| Net income per share | △¥4.85 |
| Equity ratio | End of the current fiscal period 90.2% / End of previous period 91.6% |
| Total assets | ¥1,776 million |
| Net assets | ¥1,602 million |
| Cash flows from operating activities | ¥-570,146 thousand |
| Cash flows from investing activities | ¥-10,548 thousand |
| Cash flows from financing activities | ¥240,325 thousand |
| Cash and cash equivalents at end of period | ¥1,579,970 thousand |
| Full-year earnings forecast | Net Sales Not disclosed / Operating profit Not disclosed / Ordinary income Not disclosed / Net income Not disclosed / Reason Not provided because a reasonable full-year earnings forecast cannot be calculated at this time |
| Annual Dividend Forecast | ¥0 → ¥0（0.0%） |
| Impairment loss | ¥12,359 thousand |
| Disclosure regarding the going concern assumption | A description of material events and other matters is included. Although the company recognizes that circumstances exist that raise substantial doubt about the going concern assumption, it has secured the funds necessary for its business activities for the foreseeable future and has determined that no material uncertainty exists. There are no matters to be disclosed in the notes on the going concern assumption. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement Not disclosed |
| Changes in the scope of consolidation | 0 additions (company name: —), 0 exclusions (company name: —) |
| Material subsequent events | No applicable matters. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Available (for institutional investors and analysts) |
| Issued Shares at Period-End | 153,144,288 |
| Treasury Shares at Period-End | 187 |
| Factors Behind Changes in Business Performance | Research and development expenses increased by ¥170 million due to higher development costs for emixustat hydrochloride. Selling, general and administrative expenses increased by ¥28 million due mainly to higher share-based compensation expenses and patent-related expenses. The ramp-up in overseas sales of the myopia progression care device has been delayed, and the operating loss and negative operating cash flow continue. |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Research and development expenses increased by ¥170 million due to higher development costs for emixustat hydrochloride. Selling, general and administrative expenses increased by ¥28 million, as higher share-based compensation expenses and patent-related expenses more than offset the decrease in salaries associated with the reduction in headcount. In addition, the ramp-up in overseas sales of the myopia progression care device has been delayed. The company has not provided a full-year forecast because it is difficult to accurately forecast demand for new products and research and development expenses may fluctuate significantly, making it difficult to formulate a reasonable forecast.